AU2002226064A1 - Antisense modulation of talin expression - Google Patents

Antisense modulation of talin expression

Info

Publication number
AU2002226064A1
AU2002226064A1 AU2002226064A AU2606402A AU2002226064A1 AU 2002226064 A1 AU2002226064 A1 AU 2002226064A1 AU 2002226064 A AU2002226064 A AU 2002226064A AU 2606402 A AU2606402 A AU 2606402A AU 2002226064 A1 AU2002226064 A1 AU 2002226064A1
Authority
AU
Australia
Prior art keywords
antisense modulation
talin
expression
talin expression
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002226064A
Inventor
C. Frank Bennett
Lex M Cowsert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of AU2002226064A1 publication Critical patent/AU2002226064A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002226064A 2000-10-30 2001-10-30 Antisense modulation of talin expression Abandoned AU2002226064A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/702,251 2000-10-30
US09/702,251 US6372492B1 (en) 2000-10-30 2000-10-30 Antisense modulation of talin expression
PCT/US2001/047585 WO2002036810A2 (en) 2000-10-30 2001-10-30 Antisense modulation of talin expression

Publications (1)

Publication Number Publication Date
AU2002226064A1 true AU2002226064A1 (en) 2002-05-15

Family

ID=24820437

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002226064A Abandoned AU2002226064A1 (en) 2000-10-30 2001-10-30 Antisense modulation of talin expression

Country Status (3)

Country Link
US (2) US6372492B1 (en)
AU (1) AU2002226064A1 (en)
WO (1) WO2002036810A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2875602A (en) * 2000-12-07 2002-06-18 Univ Pennsylvania Selection of catalytic nucleic acids targeted to infectious agents
BRPI0923225A2 (en) 2008-12-02 2016-10-04 Chiralgen Ltd Phosphorus-modified nucleic acid synthesis method
KR101885383B1 (en) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 Novel nucleic acid prodrugs and methods of use thereof
JP5868324B2 (en) 2010-09-24 2016-02-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ Asymmetric auxiliary group
CN103796657B (en) 2011-07-19 2017-07-11 波涛生命科学有限公司 The method for synthesizing functionalization nucleic acid
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
WO2015057727A1 (en) * 2013-10-14 2015-04-23 Isis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
KR102423317B1 (en) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 Chiral design
US10793855B2 (en) 2015-01-06 2020-10-06 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
US10407678B2 (en) 2015-04-16 2019-09-10 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5951455A (en) * 1998-12-04 1999-09-14 Isis Pharmaceuticals, Inc. Antisense modulation of G-alpha-11 expression

Also Published As

Publication number Publication date
WO2002036810A3 (en) 2003-09-18
US20040110705A1 (en) 2004-06-10
WO2002036810A2 (en) 2002-05-10
US6372492B1 (en) 2002-04-16

Similar Documents

Publication Publication Date Title
AU2001289085A1 (en) Antisense modulation of flip-c expression
AU2001277054A1 (en) Antisense modulation of lysophospholipase i expression
AU2001289046A1 (en) Antisense modulation of her-2 expression
AU2002309819A1 (en) Antisense modulation of PTP1B expression
AU2002227435A1 (en) Antisense modulation of calreticulin expression
AU2212600A (en) Antisense modulation of g-alpha-i1 expression
AU6296099A (en) Antisense modulation of g-alpha-12 expression
AU2001294926A1 (en) Antisense modulation of smad6 expression
AU2001229493A1 (en) Antisense modulation of mekk2 expression
AU5239399A (en) Antisense modulation of g-alpha-13 expression
AU2001229447A1 (en) Antisense modulation of smad7 expression
AU4325199A (en) Antisense modulation of g-alpha-11 expression
AU2001278077A1 (en) Antisense modulation of ptp1b expression
AU2001239971A1 (en) Antisense modulation of parp expression
AU2001227847A1 (en) Antisense modulation of pepck-cytosolic expression
AU6115400A (en) Antisense modulation of mekk5 expression
AU5321199A (en) Antisense modulation of inhibitor-kappa b kinase-beta expression
AU5222899A (en) Antisense modulation of inhibitor-kappa b kinase-alpha expression
AU2002366788A1 (en) Antisense modulation of ship-1 expression
AU2002226064A1 (en) Antisense modulation of talin expression
AU2002318139A1 (en) Antisense modulation of src-c expression
AU2001288968A1 (en) Antisense modulation of btak expression
AU2001257220A1 (en) Antisense modulation of inhibitor of dna binding-1 expression
AU2001283443A1 (en) Antisense modulation of hpk/gck-like kinase expression
AU2002230869A1 (en) Antisense modulation of hepsin expression